Submission of Matters to a Vote of Security Holders Form 8 K

(e) On August 6, 2024, the shareholders of Wave Life Sciences Ltd. (the "Company") approved an amendment to the Company's 2021 Equity Incentive Plan, as amended (the "Amended 2021 Equity Incentive Plan"), that increases the number of ordinary shares authorized for issuance of awards under the Amended 2021 Equity Incentive Plan by 5,000,000 shares.

A detailed summary of the material features of the Amended 2021 Equity Incentive Plan is set forth in the Company's definitive proxy statement for its 2024 Annual General Meeting of Shareholders (the "Annual Meeting") filed with the Securities and Exchange Commission on June 21, 2024 (the "Proxy Statement"). That summary and the foregoing description are qualified in their entirety by reference to the text of the Amended 2021 Equity Incentive Plan, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.